

## DAFTAR PUSTAKA

- Andayani, T.M., 2006. Analisis biaya terapi Diabetes mellitus Rumah Sakit Dr . Sardjito Yogyakarta Cost analysis of Diabetes mellitus therapy in Dr . Sardjito. *Diabetes*, **17**: 130–135.
- Banday, M.Z., Sameer, A.S., dan Nissar, S., 2020. Pathophysiology of diabetes: An overview. *Avicenna Journal of Medicine*, **10**: 174–188.
- Bennett, W.L., Singh, S., dan Segal, J.B., 2011. An update on the comparative effectiveness and safety of medications for type 2 diabetes. *Annals of Internal Medicine*, **155**: 563.
- BPS, 2018. Dalam Angka Dalam Angka. *Kota Kediri Dalam Angka*, 1–68.
- Cai, X., Gao, X., Yang, W., Han, X., dan Ji, L., 2018. Efficacy and Safety of Initial Combination Therapy in Treatment-Naïve Type 2 Diabetes Patients: A Systematic Review and Meta-analysis. *Diabetes Therapy*, **9**: 1995–2014.
- Chen, J., Wan, C.-M., Gong, S.-T., Fang, F., Sun, M., Qian, Y., dkk., 2018. Chinese clinical practice guidelines for acute infectious diarrhea in children. *World Journal of Pediatrics*, **14**: 429–436.
- Chien, C.-L., Chen, Y.-C., Malone, D.C., Peng, Y.-L., dan Ko, Y., 2020. Cost-utility analysis of second-line anti-diabetic therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin. *Current Medical Research and Opinion*, **36**: 1619–1626.
- Ciarambino, T., Crispino, P., Leto, G., Mastrolorenzo, E., Para, O., dan Giordano, M., 2022. Influence of Gender in Diabetes Mellitus and Its Complication. *International Journal of Molecular Sciences*, **23**: 1–13.
- Cooper-DeHoff, R.M., Bird, S.T., Nichols, G.A., Delaney, J.A., dan Winterstein, A.G., 2013. Antihypertensive drug class interactions and risk for incident diabetes: A nested case-control study. *Journal of the American Heart Association*, **2**: 1–8.
- Davies, M.J., Aroda, V.R., Collins, B.S., Gabbay, R.A., Green, J., Maruthur, N.M., dkk., 2022. Management of Hyperglycemia in Type 2 Diabetes. *Diabetes Care*, **45**: 2753–2786.
- Defronzo, R., Fleming, G.A., Chen, K., dan Bicsak, T.A., 2016. Metformin-associated lactic acidosis: Current perspectives on causes and risk. *Metabolism: Clinical and Experimental*, **65**: 20–29.
- Departemen Kesehatan RI, 2005. *Pharmaceutical Care Untuk Penyakit Diabetes*

*Mellitus*, Departemen Kesehatan Republik Indonesia. Departemen Kesehatan Republik Indonesia, Jakarta.

Derosa, G. dan Sibilla, S., 2007. Optimizing combination treatment in the management of type 2 diabetes. *Vascular Health and Risk Management*, **3**: 665–671.

Dewi, R., 2023. Analisis Efektivitas Penggunaan Kombinasi Antidiabetik Oral Terhadap Kadar Glukosa Darah Pada Pasien Diabetes Melitus Tipe II Di RSUD Tarakan. *Archives Pharmacia*, **2**: 78–87.

DIH, 2019. *Drug Information Handbook for Dentistry*, 25th ed, British Dental Journal. Lexicamp.

Elsayed, N.A., Aleppo, G., Aroda, V.R., Bannuru, R.R., Brown, F.M., Bruemmer, D., dkk., 2023. 2. Classification and Diagnosis of Diabetes: Standards of Care in Diabetes—2023. *Diabetes Care*, **46**: S19–S40.

Erhardt, W., Bergenheim, K., Duprat-Lomon, I., dan McEwan, P., 2012. Cost effectiveness of saxagliptin and metformin versus sulfonylurea and metformin in the treatment of type 2 diabetes mellitus in Germany: A cardiff diabetes model analysis. *Clinical Drug Investigation*, **32**: 189–202.

Fadini, G.P., Bottigliengo, D., D’Angelo, F., Cavalot, F., Bossi, A.C., Zatti, G., dkk., 2018. Comparative Effectiveness of DPP-4 Inhibitors Versus Sulfonylurea for the Treatment of Type 2 Diabetes in Routine Clinical Practice: A Retrospective Multicenter Real-World Study. *Diabetes Therapy*, **9**: 1477–1490.

Filozof, C. dan Gautier, J.F., 2010. A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with type 2 diabetes inadequately controlled with metformin alone: A 52-week, randomized study. *Diabetic Medicine*, **27**: 318–326.

Forbes, J.M. dan Cooper, M.E., 2013. Mechanisms of Diabetic Complications. *Physiol Rev*, **93**: 137–188.

Garber, A.J., Abrahamson, M.J., Barzilay, J.I., Blonde, L., Bloomgarden, Z.T., Bush, M.A., dkk., 2015. AACE/ACE comprehensive diabetes management algorithm 2015. *Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists*, **21**: 438–447.

Gause-Nilsson, I., Göke, B., Gallwitz, B., Eriksson, J., dan Hellqvist, A., 2011. Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled

trial. *International Journal of Clinical Practice*, **27**: 146–168.

Gitt, A.K., Bramlage, P., Binz, C., Krekler, M., Deeg, E., dan Tschöpe, D., 2013. Prognostic implications of DPP-4 inhibitor vs. sulfonylurea use on top of metformin in a real world setting - results of the 1 year follow-up of the prospective DiaRegis registry. *International journal of clinical practice*, **67**: 1005–1014.

Gu, S., Deng, J., Shi, L., Mu, Y., dan Dong, H., 2015. Cost-effectiveness of saxagliptin vs glimepiride as a second-line therapy added to metformin in Type 2 diabetes in China. *Journal of Medical Economics*, **18**: 808–820.

Gunawan, S. dan Rahmawati, R., 2021. Hubungan Usia, Jenis Kelamin dan Hipertensi dengan Kejadian Diabetes Mellitus Tipe 2 di Puskesmas Tugu Kecamatan Cimanggis Kota Depok Tahun 2019. *ARKESMAS (Arsip Kesehatan Masyarakat)*, **6**: 15–22.

Hardianto, D., 2021. Telaah Komprehensif Diabetes Melitus: Klasifikasi, Gejala, Diagnosis, Pencegahan, Dan Pengobatan. *Jurnal Bioteknologi & Biosains Indonesia (JBBi)*, **7**: 304–317.

Hidayat, B., Ramadani, R.V., Rudijanto, A., Soewondo, P., Suastika, K., dan Siu Ng, J.Y., 2022. Direct Medical Cost of Type 2 Diabetes Mellitus and Its Associated Complications in Indonesia. *Value in Health Regional Issues*, **28**: 82–89.

Kemenkes RI, 2013. *Buku Pedoman Farmakoekonomi*, 2013th ed, Kementerian Kesehatan RI. Kementerian Kesehatan RI, Jakarta.

Kim, D.D., Silver, M.C., Kunst, N., Cohen, J.T., Ollendorf, D.A., dan Neumann, P.J., 2020. Perspective and Costing in Cost-Effectiveness Analysis, 1974–2018. *Pharmacoeconomics*, **38**: 1135–1145.

Kumar, V., Aranha, V., Rajgarhia, R., Royal, A., dan Mehta, K., 2021. Expanded principles of ethics and its implementation during COVID-19 vaccine trials: A scoping evidence based research synthesis. *Human Vaccines and Immunotherapeutics*, **17**: 3843–3849.

Kusumawati, N.N. dan Andayani, T.M., 2024. Review : Cost-Effectiveness Analysis Metformin + Dipeptidyl Peptidase-4 Inhibitors Dibandingkan dengan Metformin + Sulfonilurea pada Pasien Diabetes Mellitus Tipe 2. *Journal of Pharmaceutical Science and Clinical Research*, **9**: 326–338.

Kwon, C.S., Seoane-Vazquez, E., dan Rodriguez-Monguio, R., 2018. Cost-effectiveness analysis of metformin+dipeptidyl peptidase-4 inhibitors compared to metformin+sulfonylureas for treatment of type 2 diabetes. *BMC*

*Health Services Research*, **18**: 1–12.

Leander, D.J. dan Tahapary, D.L., 2021. Pemilihan Obat Antidiabetik Oral pada Pasien Diabetes Melitus Tipe 2 dengan Risiko Tinggi untuk Kejadian Kardiovaskular. *Jurnal Penyakit Dalam Indonesia*, **7**: 240.

Lee, P.G. dan Halter, J.B., 2017. The pathophysiology of hyperglycemia in older adults: Clinical considerations. *Diabetes Care*, **40**: 444–452.

Mursalin dan Soewondo, P., 2017. Analisis Estimasi Biaya Langsung Medis Penderita Rawat Jalan Diabetes Mellitus Tipe 2 di RSUD Dr. Abdul Aziz Singkawang Tahun 2013. *Jurnal Ekonomi Kesehatan Indonesia*, **1**: 5–15.

Nathan, D.M., Buse, J.B., Davidson, M.B., Ferrannini, E., Holman, R.R., Sherwin, R., dkk., 2009. Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. *Diabetes Care*, **32**: 193–203.

Ong, K.L., Stafford, L.K., McLaughlin, S.A., Boyko, E.J., Vollset, S.E., Smith, A.E., dkk., 2023. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. *The Lancet*, **402**: 203–234.

Parida, S., Swain, T.R., Routray, S.N., dan Maiti, R., 2017. Effect of atorvastatin on glycaemic parameters in normoglycaemic and prediabetic subjects: A prospective, panel study. *Journal of Clinical and Diagnostic Research*, **11**: FC04–FC09.

Pavlicek, V., 2024. Impact of type 2 diabetes mellitus on life expectancy in people with heart failure. *Diabetologie*, **20**: 587–588.

PERKENI, 2019. Pengelolaan Dan Pencegahan Diabetes Melitus Tipe 2 Dewasa di Indonesia. *PB Perkeni*, 133.

PERKENI, 2021. *Pedoman Pengelolaan Dan Pencegahan Diabetes Melitus Tipe 2 Dewasa Di Indonesia 2021*, 2021st ed, Perkeni. PB PERKENI, Indonesia.

Purnamasari, T.J., Ilone, S., dan Setiawan, D., 2023. Cost Utility Analysis Vildagliptin dan Glimpiride dalam Mencegah Komplikasi Mikrovaskuler menggunakan Model Markov. *JURNAL MANAJEMEN DAN PELAYANAN FARMASI (Journal of Management and Pharmacy Practice)*, **13**: 266–277.

Rahayu, L., Yantih, N., dan Supomo, Y., 2018. Analysis of SGPT and SGOT in Isoniazid-Induced Mice for Dosage Determination and Hepatoprotective Characteristics of Raw Pineapple (*Ananas comosus* L. Merr) Water. *JIFI*, **16**: 100–106.

- Rani, C.C. dan Mulyani, N.S., 2021. Faktor-faktor yang berhubungan dengan kejadian diabetes mellitus tipe-II pada pasien rawat jalan. *Jurnal SAGO Gizi dan Kesehatan*, **2**: 122.
- Saeedi, P., Petersohn, I., Salpea, P., Malanda, B., Karuranga, S., Unwin, N., dkk., 2019. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. *Diabetes Research and Clinical Practice*, **157**: 107843.
- Sari, D.O., Lorensia, A., Rahem, A., dan Lestiono, L., 2023. Uji Efektivitas Dan Keamanan Kombinasi Metformin-Vildagliptin Pada Diabetes Melitus Tipe 2 Di Rspal Dr. Ramelan Surabaya. *Jurnal Ilmiah Ibnu Sina (JIIS): Ilmu Farmasi dan Kesehatan*, **8**: 166–175.
- Schopman, J.E., Simon, A.C.R., Hoefnagel, S.J.M., Hoekstra, J.B.L., Scholten, R.J.P.M., dan Holleman, F., 2014. The incidence of mild and severe hypoglycaemia in patients with type 2 diabetes mellitus treated with sulfonylureas: A systematic review and meta-analysis. *Diabetes/Metabolism Research and Reviews*, **30**: 11–22.
- Setiawan, D., 2017. *Farmakoekonomi Modelling*, 2017th ed. UM Purwokerto Perss, Purwokerto.
- Sinaga, M., 2022. Gambaran Karakteristik Pasien Diabetes Melitus Di Rumah Sakit RSUP Haji Adam Malik Medan Tahun 2020. *Jurnal Ilmiah Multi Disiplin Indonesia*, **2**: 681–688.
- Standl, E., Schnell, O., dan McGuire, D.K., 2016. Heart failure considerations of antihyperglycemic medications for type 2 diabetes. *Circulation Research*, **118**: 1830–1843.
- Stumvoll, M., Goldstein, B.J., dan Haeflten, T.W. Van, 2005. Haeflten\_Pathogenesis of type 2 diabetes.pdf. *The Lancet*, **365**: 1333–1346.
- Suraj, B., Tripathi, C.D., Biswas, K., Padhy, B.M., dan Arora, T., 2015. A Comparative Evaluation of Safety, Efficacy and Cost Effectiveness of Three Add on Treatment Regimens in Type 2 Diabetics; Not Controlled by Metformin Alone. *Research Journal of Pharmacy and Technology*, **8**: 44–50.
- Timur, W.W. dan Pradesti, A.N., 2024. Perbedaan Efektivitas Penggunaan Metformin-Insulin versus Metformin-Vildagliptin Terhadap Profil Glikemik Pasien DMT2 di Instalasi Rawat Jalan RSISA Periode 2022. *JPSCR: Journal of Pharmaceutical Science and Clinical Research*, **9**: 1.
- USA, T.O. of R.I.-, 2024. 'Elements of Research (Variables)', . URL:

<https://ori.hhs.gov/education/products/sdsu/variables.htm> (diakses tanggal 23/3/2024).

Valderas, J.M., Starfi, B., dan Sibbald, B., 2009. Understanding Health and Health Services. *Annals Of Family Medicine*, **7**: 357–363.

Viriato, D., Calado, F., Gruenberger, J.B., Ong, S.H., Carvalho, D., Silva-Nunes, J., dkk., 2014. Cost-effectiveness of metformin plus vildagliptin compared with metformin plus sulphonylurea for the treatment of patients with type 2 diabetes mellitus: A Portuguese healthcare system perspective. *Journal of Medical Economics*, **17**: 499–507.

Wangiyana, W., Aryana, I.G.P.M., dan Farida, N., 2022. Synergistic effect of straw-mulch and mycorrhiza-biofertilizer in increasing yield of black rice intercropped with soybean on raised-beds in aerobic irrigation system. *Emirates Journal of Food and Agriculture*, **34**: 971 – 981.

WHO, 2016. *Global Report on Diabetes*, Isbn. World Health Organization, France.  
Yu, M.K., Lyles, C.R., Bent-Shaw, L.A., dan Young, B.A., 2013. Sex disparities in diabetes process of care measures and self-care in high-risk patients. *Journal of Diabetes Research*, **2013**: 1–8.

Zang, L., Han, Y., Chen, L., Hu, D., Jin, H., Yang, N., dkk., 2019. Comparison of the Effectiveness and Safety of Vildagliptin Add-On to Metformin Versus Other Oral Dual Antidiabetes Agents in Patients with Type 2 Diabetes: The China Prospective Diabetes Study. *Diabetes Therapy*, **10**: 1391–1405.

Zhang, Y., McCoy, R.G., Mason, J.E., Smith, S.A., Shah, N.D., dan Denton, B.T., 2014. Second-line agents for glycemic control for type 2 diabetes: Are newer agents better? *Diabetes Care*, **37**: 1338–1345.

Zierle-Ghosh, A. dan Jan, A., 2023. Physiology, Body Mass Index. *StatPearls*, .